Can next-generation vaccines help close the gap between innovation and global health equity?

In our new review published in Frontiers in Immunology — “GenIV vaccines: bridging innovation to equity in neglected tropical diseases” — we explore how fourth-generation vaccines (GenIV), including mRNA platforms, could transform the fight against diseases such as leishmaniasis.

Beyond the science, the challenge is also about access, technology transfer, and regional manufacturing.

At GEG-Tech, we are also actively working on the development of biological mRNA vaccines targeting malaria, leishmaniasis, and Clostridioides difficile, with very promising preliminary preclinical results.

Advances in vectorology and RNA delivery are opening a new chapter in vaccinology — one where cutting-edge innovation can truly meet global health needs.

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1756570/full